Nathan J. Dowden, Chief Operating Officer at Entrada Therapeutics, Inc. (TRDA), sold 31,964 shares at $16.02 ($493K) on 2023-06-22, disclosed to the SEC on 2023-06-22.
Scheduled sale ($493k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.94 | 8,885 | $133K | 26.9% |
| 2 | $14.94 | 8,885 | $133K | 26.9% |
| 3 | $16.02 | 7,097 | $114K | 23.1% |
| 4 | $16.02 | 7,097 | $114K | 23.1% |
| Total | $15.42 avg | 31,964 | $493K | 100% |
| Filing → |
| TRDA | SELL | 2024-09-30 | $14K | — | Filing → |
| TRDA | SELL | 2024-09-10 | $35K | — | Filing → |
| TRDA | SELL | 2024-08-20 | $873K | — | Filing → |